Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

Boston Scientific, Inc. BSX recently announced receiving the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device. The latest device is intended to ...

After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...

In-hospital safety and procedural outcomes for percutaneous left atrial appendage (LAA) closure are substantially better with the Watchman FLX device than with its predecessor, new research shows.

The Watchman FLX met primary safety and effectiveness endpoints in an observational study of the next-generation transcatheter left atrial appendage (LAA) closure device. Designed to improve upon the ...

The Heart Institute of East Texas proudly introduces the latest advancement in cardiac care with the implementation of the Watchman Flx Pro Left Atrial Appendage Occluder implantation technology. This ...

Boston Scientific has obtained an FDA green light for the latest version of its Watchman heart implant, designed to help lower the risk of stroke in patients with atrial fibrillation. Compared to its ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...